Clinical Study of Single-Injection Bupivacaine Liposomal in Infraspinatus-Teres Minor Interfascial Block for Arthroscopic Shoulder Surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500105850

Enrollment

Unknown

Registered

2025-07-14

Start date

2025-07-31

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator cuff injury

Interventions

BL Group:Bupivacaine liposome 266mg 20ml

M Group:0.375% Bupivacaine 10ml+Bupivacaine liposome 133mg 10ml

B Group:0.375% Bupivacaine 20ml

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age > 50 years 2.Scheduled for arthroscopic shoulder surgery 3.ASA physical status classification I-II 4.Informed consent obtained and documented

Exclusion criteria

Exclusion criteria: 1.Active infection at the needle insertion site 2.Significant coagulation abnormalities (INR > 1.5 or platelet count < 100×10?/L)* 3.Severe dysfunction of major organ systems (cardiopulmonary/cerebral/renal) 4.Allergy to any study medication 5.Inability to comply with follow-up procedures 6.Cognitive impairment precluding reliable questionnaire completion

Design outcomes

Primary

Measure	Time frame
Numeric graded score of pain, NRS;	—

Secondary

Measure	Time frame
Block Efficacy;Hemodynamics(MAP, HR, SPO2);Intraoperative propofol and remifentanil consumption;Intraoperative Vasoactive Agent Consumption;Postoperative Rescue Analgesic Consumption;QoR-15 score;Constant-Murley score;Side effect;Patient satisfaction;Surgeon satisfaction;	—

Countries

China

Contacts

Public ContactRen Yucheng

Dafeng People’s Hospital, Yancheng

xyrenyucheng@163.com+86 173 1298 8907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026